A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma

Overview of attention for article published in Oncologist, September 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 1 news outlet
twitter: 21 X users

facebook: 1 Facebook page

So far, Altmetric has seen 1 news story.

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.

Weather herald, 09 Sep 2019

5 hours ago HyperAcute Renal immunotherapy turned into well tolerated and verified antitumor activity in patients requiring…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.